| Name | Title | Contact Details |
|---|
East Alabama Ears Nose and Throat Pc is a Opelika, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Visionix is a Blue Bell, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Mastercraft Dental Co of Texas is a Midlothian, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Katalyst Surgical is the industry leader in ophthalmic surgical instruments. Our experienced team has over 40 years of design, manufacturing, and quality control of ophthalmic surgical products. It is our goal to provide superior service paired with high quality ophthalmic products at a cost saving to our customers. We stand by our company-wide policy that the customer is always right... By continually gathering customer feedback and working with our highly skilled professional team, Katalyst Surgical continues to deliver unmatched ophthalmic instruments while increasing our number of loyal customers. Katalyst Surgical is a premier research and development facility... Keeping up with cutting edge products and the changing industry has allowed us to serve our customers with 100% satisfaction Superior products within your budget... Your business is important to our team at Katalyst Surgical. Our goal is to offer superior products with premium customer service within your budget. Committed to our customers... We greatly appreciate your feedback on our ophthalmic surgical instruments and repair services.
HeartBeam, Inc. (NASDAQ: BEAT) is a development stage digital healthcare company with proprietary ECG telemedicine technology that will redefine the way high risk cardiovascular patients are diagnosed in an ambulatory setting at any time and any place. Its breakthrough solution employs a reusable, credit card sized, 3D vector ECG recording device and cloud-based software capable of assisting a physician in diagnosing a wide range of cardiovascular disease. HeartBeam is initially focusing on a huge unmet need of helping diagnose heart attacks in patients outside of a medical institution. No single lead ECG technology can offer this value to patients and their physicians. This underserved market is several times larger than the cardiac arrhythmia detection market based on the prevalence of patients with coronary artery disease at high risk of heart attack